Sort
48,018 grants matching “immunotherapy”
Control of regulatory T cell fitness and function by heme synthesis
$647,187Xudong Li · Tufts University Boston · R01 · FY2025 · AI
Deciphering the role of EYA3/PP2A in triple negative breast cancer metastasis
$647,118Heide L Ford · University Of Colorado Denver · R01 · FY2025 · CA
The role of brain resident T cells in Alzheimer's disease
$647,086Pamela Rosato · Dartmouth College · R01 · FY2024 · AG
Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance
$647,072Roger S Lo · University Of California Los Angeles · R01 · FY2025 · CA
Project 2: Radiation-Induced Lymphopenia: Understanding, Predictive Modeling and Developing Photon and Proton-Based Mitigation Strategies.
$647,018Steven Hsesheng Lin · Massachusetts General Hospital · P01 · FY2021 · CA
Redox Mechanism Process of Angiogenesis and Wound Healing
$646,842David Wink · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Frequency and phenotype of Fel d 1-specific T cells after peptide therapy
$646,764Mark Larche · Mcmaster University · U19 · FY2013 · AI
Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer
$646,719Alejandro Gutierrez · St. Jude Children'S Research Hospital · R01 · FY2025 · CA
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$646,659Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA
Novel regulatory mechanisms and agonists of STING
$646,571Xuewu Zhang · Ut Southwestern Medical Center · R01 · FY2024 · CA
Metabolic impact on T cell-mediated cancer immunity and therapy
$646,476Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Metabolic impact on T cell-mediated cancer immunity and therapy
$646,425Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
Novel immunological biomarkers ovarian cancer prognosis
$646,389Brahm H. Segal · Roswell Park Cancer Institute Corp · R01 · FY2017 · CA
Novel immunological biomarkers ovarian cancer prognosis
$646,389Brahm H. Segal · Roswell Park Cancer Institute Corp · R01 · FY2016 · CA
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastases
$646,356Elizabeth Gerstner · Massachusetts General Hospital · R01 · FY2024 · CA
Sexual dimorphism and the immuno-modulatory role of estrogen signaling in HNSCC
$646,344Sana D Karam · University Of Colorado Denver · R01 · FY2023 · CA
IMMUNOTHERAPY OF MELANOMA: TARGETING HELIOS IN THE TUMOR MICROENVIRONMENT FOR EFFECTOR CELL CONVERSION
$646,313Dana-Farber Cancer Institute, Inc. · · FY2017 · Department of the Army
Novel Monoclonal Antibody Therapy for Cancer
$646,303Galaxy Biotech, Llc · R44 · FY2005 · CA
Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome
$646,181Verena Staedtke · Johns Hopkins University · U01 · FY2020 · CA
Immunotherapeutics Against Other Filovirus Threats
$646,170Jonathan R. Lai · Scripps Research Institute, The · U19 · FY2016 · AI
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
$646,146Robert H Vonderheide · University Of Pennsylvania · P01 · FY2021 · CA
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
$646,136Henrieta Scholtzova · New York University School Of Medicine · R01 · FY2019 · NS
Selective disruption of histone deacetylase complexes using protein interaction modulators
$646,119Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Mouse models of Kras-mutant colorectal cancer
$646,021Kevin Michael Haigis · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric
$645,998Heike Elizabeth Daldrup-Link · Stanford University · R01 · FY2022 · CA